Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06921460

Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV

Sponsor: PT Bio Farma

View on ClinicalTrials.gov

Summary

Typhoid fever is a serious systemic infection caused by the enteric pathogen Salmonella enterica serovar typhi. S typhi is spread by the fecal-oral route. Although largely an endemic disease, S. typhi has epidemic potential. This research aims to determine the long-term immune response after administration of one dose of Bio TCV and PQed TCV vaccines in the population in Indonesia. Research participants will be taken from research participants who complete the Bio TCV (Typhoid 0319) Phase III clinical trial research included in the Main Study Group I.

Official title: Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines (Bio TCV) in Indonesian Population Compared to PQed TCV

Key Details

Gender

All

Age Range

6 Months - 60 Years

Study Type

OBSERVATIONAL

Enrollment

624

Start Date

2025-06-15

Completion Date

2025-12-31

Last Updated

2025-06-03

Healthy Volunteers

Yes

Locations (1)

Department of Child Health Dr. Soetomo Hospital/School of Medicine, Airlangga University, Surabaya, East Java

Jakarta, DKI Jakarta, Indonesia